Erman Akkus: Genome targeted cancer therapies in NCCN guidelines according to the ESMO MCBS and ESCAT

Erman Akkus, Medical Oncology Fellow at Ankara University Faculty of Medicine, shared a post on X:

“Genome targeted cancer therapies in National Comprehensive Cancer Network (NCCN) guidelines according to the ESMO MCBS and ESCAT.

411 recommendations:

• 16% relied on only case reports or pre-clinical studies
• 78% of clinical trials are phase I/II
• 76% of clinical trials are single arm
• In 78%, primary endpoint is ORR
• 60% is ESCAT tier 1
• Only 12% showed substantial clinical benefit (ESMO-MCBS grades 4-5).”

Source: Erman Akkus/X

Clinical value of guideline recommended molecular targets and genome targeted cancer therapies: cross sectional study.

Authors: Ariadna Tibau, Thomas J Hwang, Jerry Avorn, and Aaron S Kesselheim.